Ultragenyx reported preliminary unaudited 2025 revenue results exceeding the top end of guidance.
Preliminary cash and investments were approximately $735 million as of December 31, 2025.
Anticipated 2026 catalysts include potential approvals and pivotal Phase 3 data from the GTX-102 study.
2025 Revenue
Estimated total revenue of $672-674 million, surpassing guidance.
Cash Position
Approximately $735 million cash and investments as of December 31, 2025.
2026 Catalysts
Expected approvals and Phase 3 data anticipation.
- 2025 marked significant revenue growth exceeding guidance by 20%.
- Strategic investments position Ultragenyx for transformative developments in 2026.
Ultragenyx's impressive revenue results and solid cash position set a strong foundation for upcoming catalysts and growth opportunities in 2026.